EAN Congress news
EAN 2019: Focused Workshop 12 – Autologous hematopoietic stem cell transplantation in multiple sclerosis
Autologous hematopoietic stem cell transplantation (HSCT) is a promising treatment option for multiple sclerosis (MS). The premise of the treatment is that the self-reactive immune response is eradicated by chemotherapy, and that the immune system is "reset" after reinfusion of autologous hematopoietic stem cells, producing an immune system that is less self-reactive.